AR051997A1 - Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos - Google Patents
Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticosInfo
- Publication number
- AR051997A1 AR051997A1 ARP050105285A ARP050105285A AR051997A1 AR 051997 A1 AR051997 A1 AR 051997A1 AR P050105285 A ARP050105285 A AR P050105285A AR P050105285 A ARP050105285 A AR P050105285A AR 051997 A1 AR051997 A1 AR 051997A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- atoms
- alkoxy
- ring
- halogen
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 21
- 229910052736 halogen Inorganic materials 0.000 abstract 16
- 150000002367 halogens Chemical class 0.000 abstract 16
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000004429 atom Chemical group 0.000 abstract 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000002619 bicyclic group Chemical group 0.000 abstract 8
- 125000002950 monocyclic group Chemical group 0.000 abstract 8
- -1 cyano, nitro, amino, hydroxy Chemical group 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000006413 ring segment Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- XYTURHNISUUOQJ-UHFFFAOYSA-N [cyano(nitro)amino] hydrogen sulfate Chemical compound C(#N)N(OS(=O)(=O)O)[N+](=O)[O-] XYTURHNISUUOQJ-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04030114 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051997A1 true AR051997A1 (es) | 2007-02-21 |
Family
ID=34927856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105285A AR051997A1 (es) | 2004-12-17 | 2005-12-15 | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060142247A1 (de) |
| EP (1) | EP1831224A2 (de) |
| JP (1) | JP2008524151A (de) |
| KR (1) | KR20070086336A (de) |
| CN (1) | CN101080408A (de) |
| AR (1) | AR051997A1 (de) |
| AU (1) | AU2005315783A1 (de) |
| BR (1) | BRPI0519567A2 (de) |
| CA (1) | CA2589051A1 (de) |
| MX (1) | MX2007006129A (de) |
| TW (1) | TW200635923A (de) |
| WO (1) | WO2006063841A2 (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2001882A1 (de) * | 2006-03-23 | 2008-12-17 | F. Hoffmann-La Roche AG | Substituierte indazolderivate, ihre herstellung und verwendung als pharmazeutische wirkstoffe |
| US20080153810A1 (en) * | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| GB0708507D0 (en) * | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
| US20090063623A1 (en) * | 2007-08-31 | 2009-03-05 | International Business Machines Corporation | Determining connection information to use to access an artifact from an application on a remote server |
| MX2011003429A (es) | 2008-10-13 | 2011-05-02 | Hoffmann La Roche | Metodo libre de diazonio para fabricar un compuesto intermedio de indazol en la sintesis de las amidas del acido 5-(trifluorometoxi)-1h-3-indazolcarboxilico biciclico. |
| JP5763072B2 (ja) | 2009-08-10 | 2015-08-12 | サミュメッド リミテッド ライアビリティ カンパニー | Ｗｎｔシグナル経路のインダゾール阻害剤およびその治療的使用 |
| RS56669B1 (sr) | 2009-12-21 | 2018-03-30 | Samumed Llc | 1h-pirazolo[3,4-b]piridini i njihove terapeutske primene |
| HUE041576T2 (hu) | 2011-09-14 | 2019-05-28 | Samumed Llc | Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| NZ741907A (en) | 2012-05-04 | 2020-02-28 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| EP2895476B1 (de) | 2012-09-13 | 2016-06-22 | F.Hoffmann-La Roche Ag | 2-oxo-2,3-dihydro-indole zur behandlung von zns-erkrankungen |
| CA2897400A1 (en) | 2013-01-08 | 2014-07-17 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
| CN104098513B (zh) * | 2014-07-30 | 2016-08-24 | 天津市斯芬克司药物研发有限公司 | 一种吲唑化合物衍生物及其制备方法 |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10899757B2 (en) | 2015-11-06 | 2021-01-26 | Samumed, Llc | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| RS63813B1 (sr) | 2016-06-01 | 2023-01-31 | Biosplice Therapeutics Inc | Postupak pripreme n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida |
| RU2770613C2 (ru) | 2016-10-21 | 2022-04-19 | СЭМЬЮМЕД, ЭлЭлСи | Способы применения индазол-3-карбоксамидов и их применение в качестве ингибиторов сигнального пути wnt/в-катенина |
| US10758523B2 (en) | 2016-11-07 | 2020-09-01 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL144822B1 (en) * | 1984-05-12 | 1988-07-30 | Boehringer Mannheim Gmbh | Method of obtaining novel pyrolobenzimidazoles |
| US4835280A (en) * | 1985-01-18 | 1989-05-30 | Boehringer Mannheim Gmbh | Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles |
| DE3501497A1 (de) * | 1985-01-18 | 1986-07-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
| DE3642315A1 (de) * | 1986-12-11 | 1988-06-23 | Boehringer Mannheim Gmbh | Neue pyrrolobenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
| DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| DE3803775A1 (de) * | 1988-02-09 | 1989-08-17 | Boehringer Mannheim Gmbh | Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| FR2831536A1 (fr) * | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
-
2005
- 2005-12-13 US US11/301,993 patent/US20060142247A1/en not_active Abandoned
- 2005-12-14 TW TW094144191A patent/TW200635923A/zh unknown
- 2005-12-15 AR ARP050105285A patent/AR051997A1/es not_active Application Discontinuation
- 2005-12-16 CN CNA2005800428367A patent/CN101080408A/zh active Pending
- 2005-12-16 WO PCT/EP2005/013557 patent/WO2006063841A2/en not_active Ceased
- 2005-12-16 AU AU2005315783A patent/AU2005315783A1/en not_active Abandoned
- 2005-12-16 BR BRPI0519567-5A patent/BRPI0519567A2/pt not_active IP Right Cessation
- 2005-12-16 JP JP2007545960A patent/JP2008524151A/ja active Pending
- 2005-12-16 CA CA002589051A patent/CA2589051A1/en not_active Abandoned
- 2005-12-16 EP EP05818410A patent/EP1831224A2/de not_active Withdrawn
- 2005-12-16 MX MX2007006129A patent/MX2007006129A/es not_active Application Discontinuation
- 2005-12-16 KR KR1020077013678A patent/KR20070086336A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW200635923A (en) | 2006-10-16 |
| BRPI0519567A2 (pt) | 2009-01-27 |
| CN101080408A (zh) | 2007-11-28 |
| MX2007006129A (es) | 2007-07-13 |
| EP1831224A2 (de) | 2007-09-12 |
| US20060142247A1 (en) | 2006-06-29 |
| JP2008524151A (ja) | 2008-07-10 |
| CA2589051A1 (en) | 2006-06-22 |
| WO2006063841A2 (en) | 2006-06-22 |
| AU2005315783A1 (en) | 2006-06-22 |
| KR20070086336A (ko) | 2007-08-27 |
| WO2006063841A3 (en) | 2006-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| ECSP077323A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| MX2021013135A (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. | |
| UY30327A1 (es) | Nuevos compuestos ii | |
| AR026122A1 (es) | Derivados de 3(5)-amino-pirazol, procedimiento para su preparacion y su uso como agente antitumorales | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| UY29420A1 (es) | Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |